Product image of Iluvien (Fluocinolone Acetonide) supplied by GNH India

Iluvien

Active Ingredient:
Fluocinolone Acetonide
Origin:
EU

Iluvien (Fluocinolone Acetonide)

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It is indicated for the treatment of diabetic macular edema in adult patients, providing long‑term anti‑inflammatory and anti‑vascular permeability effects within the retina.

GNH India supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide under EU‑approved standards. The company supports regulatory documentation, cold‑chain logistics and post‑market surveillance for its ophthalmic implant portfolio globally.

Manufacturer / TM Owner

Alimera Sciences Europe Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Iluvien (fluocinolone acetonide) is used to manage ocular conditions characterized by retinal edema and vascular leakage.
  • Diabetic macular edema: reduces retinal swelling and can improve visual acuity.

How It Works

  • Fluocinolone acetonide binds to intracellular glucocorticoid receptors in retinal cells, altering gene transcription. This suppresses inflammatory cytokine production, stabilizes the blood‑retinal barrier, decreases vascular permeability, and limits leukocyte migration, thereby reducing retinal edema and preventing further tissue damage.

Side Effects

Iluvien may cause ocular adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Increased intraocular pressure
  • Cataract formation or progression
  • Ocular pain or discomfort
  • Decreased visual acuity

Serious or Rare Side Effects

  • Retinal detachment
  • Endophthalmitis (intraocular infection)
  • Vitreous hemorrhage
  • Severe optic nerve damage

Precautions & Warnings

Prior to implantation, clinicians should evaluate patients for factors that may increase the risk of complications.

  • Monitor intraocular pressure: schedule regular IOP assessments after implantation.
  • Assess cataract status: consider baseline lens opacity and potential progression.
  • Avoid in active ocular infection: postpone implantation until infection resolves.
  • Use caution in glaucoma patients: evaluate risk of steroid‑induced pressure rise.
  • Review systemic corticosteroid exposure: limit concurrent systemic steroids when possible.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Iluvien can interact with other medications that affect corticosteroid activity or ocular physiology.

Major Interactions (Avoid)

  • Systemic corticosteroids: additive glucocorticoid effects may increase systemic exposure.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise intraocular drug levels.
  • Antifungal azoles: potential increase in fluocinolone concentration.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect.
  • Anti‑VEGF agents: coordinate timing to avoid overlapping procedures.

Frequently Asked Questions

Iluvien is a fluocinolone acetonide intravitreal implant indicated for the treatment of diabetic macular edema in adult patients. It delivers a low‑dose corticosteroid directly to the retina over an extended period to reduce swelling and improve visual function. The device is designed to release the drug continuously for up to 36 months, providing a long‑acting therapeutic option that may reduce the need for frequent injections.

Fluocinolone acetonide binds to intracellular glucocorticoid receptors in retinal cells, altering gene transcription. This action suppresses production of inflammatory cytokines, stabilizes the blood‑retinal barrier, decreases vascular permeability, and limits leukocyte migration, thereby reducing retinal edema and preventing further damage. The anti‑inflammatory effect is sustained because the implant releases a low, steady dose directly into the vitreous cavity, achieving therapeutic concentrations while minimizing systemic exposure.

The prescribed dose of Iluvien is determined by the treating ophthalmologist. The product is supplied as a single‑use 0.19 mg fluocinolone acetonide intravitreal implant that is inserted into the eye during a minor surgical procedure. The frequency of implantation depends on the individual’s response and clinical judgment.

The safety of Iluvien in pregnant or lactating women has not been established, and the product is classified as pregnancy category unknown. Because systemic exposure is low but not negligible, the drug should only be used if the potential benefit justifies the potential risk, and it is

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fluocinolone Acetonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT